Tom Frohlich

Tom Frohlich

Chief Executive Officer, President and DirectoratJade Biosciences· In proxies 2024–2025

Pay in FY2025+618% from the year before · Jade Biosciences stock +59.2% the same year

Tom Frohlich was paid $9.8M in FY2025 (Dec), up 618%. Jade Biosciences stock rose 59.2% that year.

Pay$100 in the stock at the end of FY23 → $19
Pay is from the Summary Compensation Table of each Jade Biosciences proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. Jade BiosciencesPublic company · 2 yr
    • Chief Executive Officer, President and Director2024 – Present · 2 yrStock in role -83%

Roles come from the proxy statements of each company.

Boards1

  • Jade BiosciencesDirector · 0 yr on the boardNot independent—Paid as an executive

Board seats come from each company's latest proxy statement.

Activity

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?